The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer
OBJECTIVE: To investigate the utility of fluorescence in situ hybridization (FISH) in secondary electroresection of bladder cancer.
METHODS: From January 2016 to April 2022, bladder cancer patients who had undergone secondary electroresection in Tongji Hospital and had preoperative urine FISH were recruited, and the positive rate, accuracy, sensitivity, specificity, genetic material changes and predictive power on malignancy degree of FISH in the secondary electroresection of bladder cancer were examined.
RESULTS: Twenty-six patients with bladder cancer were included in this study, and 8 were confirmed by secondary electroresection, including 6 cases positive for FISH positive and 2 negative for FISH. Besides, among the subjects, 18 were without tumor recurrence, including 1 case with positive FISH results and 17 with negative FISH results. Tumor recurrence was diagnosed in 85.71% (6/7) of FISH-positive patients in secondary electroresection while only 10.53% (2/19) of FISH-negative patients were found to develop tumor recurrence in the secondary electroresection. The sensitivity of FISH for the detection of bladder cancer before secondary electroresection was 75%, with a specificity of 94.44%, and an accuracy of 88.46%. A 6-month follow-up revealed that 2 of the 8 recurrent patients underwent radical resection of bladder cancer, and the remaining 6 patients had no recurrence, as confirmed by regular bladder perfusion and microscopy. In the 18 non-recurrent patients during secondary electroresection, no recurrence developed.
CONCLUSIONS: Urine FISH can achieve a high detection rate and specificity for secondary electroresection of bladder cancer. If a bladder cancer patient who are indicated for secondary electroresection is negative for urine FISH, the recurrence rate after secondary electroresection will be low, and the cystoscopy can be performed before deciding whether to perform secondary electroresection.
1. Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022 Jan;81(1):75–94. https://doi.org/10.1016/j.eururo.2021.08.010 PMID:34511303
2. Wu KJ, Zng X, He DL.The optimal indications and standardized surgical procedures of second TURBT for bladder cancer. Journal of Modern Urology. 2020 July;25(7):570-4. Chinese.
3. Li LY, Jiang JY, Liu JJ, Li SB, Gao SY. UroVysion fluorescence in situ hybridization for monitoring the recurrence of bladder cancer. Journal of Medical Postgraduates. 2011 May;24(5):516–9.Chinese.
4. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003 Jun;169(6):2101–5. https://doi.org/10.1097/01.ju.0000066842.45464.cc
5. Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 2013 Oct;121(10):591–7. https://doi.org/10.1002/cncy.21327 PMID:23801650
6. Yan W, Kang WT, Chen S, Liu YX. Clinical value of fluorescence in situ hybridization in early detection of postoperative recurrence of bladder urothelial cancer. Journal of Capital Medical University. 2014 June;35(3):298-301.
7. Herr HW. Role of re-resection in non-muscle-invasive bladder cancer. ScientificWorldJournal. 2011 Feb;11:283–8. https://doi.org/10.1100/tsw.2011.29 PMID:21298219
8. Li SL, Wang XH, Wang HP, Chen HY. Clinical Effect of Repeat Resection after Transurethral Resection of Superficial Bladder Tumor with Plasmakinetic. Clinical Medicine & Engineering. 2011 June;18(6):827-8. Chinese.
9. Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 2013 Oct;121(10):591–7. https://doi.org/10.1002/cncy.21327 PMID:23801650
10. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003 Jun;169(6):2101–5. https://doi.org/10.1097/01.ju.0000066842.45464.cc PMID:1277172711
11. Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, et al. Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial. J Urol. 2012 Mar;187(3):862–7. https://doi.org/10.1016/j.juro.2011.10.144 PMID:22245325
12. Calò B, Chirico M, Fortunato F, Sanguedolce F, Carvalho-Dias E, Autorino R, et al. Is Repeat Transurethral Resection Always Needed in High-Grade T1 Bladder Cancer? Front Oncol. 2019 Jun;9:465. https://doi.org/10.3389/fonc.2019.00465 PMID:31214506
13. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, et al. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World J Urol. 2018 Oct;36(10):1621–7. https://doi.org/10.1007/s00345-018-2299-2 PMID:2972161114
14. Bosschieter J, Lutz C, Segerink LI, Vis AN, Zwarthoff EC, A van Moorselaar RJ, et al. The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review. Epigenomics. 2018 May;10(5):673–687. https://doi.org/10.2217/epi-2017-0156 PMID:29692199